Correlation Between Lyra Therapeutics and Immunome

Can any of the company-specific risk be diversified away by investing in both Lyra Therapeutics and Immunome at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Lyra Therapeutics and Immunome into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Lyra Therapeutics and Immunome, you can compare the effects of market volatilities on Lyra Therapeutics and Immunome and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Lyra Therapeutics with a short position of Immunome. Check out your portfolio center. Please also check ongoing floating volatility patterns of Lyra Therapeutics and Immunome.

Diversification Opportunities for Lyra Therapeutics and Immunome

0.73

Correlation Coefficient

Lyra Therapeutics  Immunome

Poor diversification

The 3 months correlation between Lyra and Immunome is 0.73. Overlapping area represents the amount of risk that can be diversified away by holding Lyra Therapeutics and Immunome in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Immunome and Lyra Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Lyra Therapeutics are associated (or correlated) with Immunome. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Immunome has no effect on the direction of Lyra Therapeutics i.e., Lyra Therapeutics and Immunome go up and down completely randomly.

Pair Corralation between Lyra Therapeutics and Immunome

Given the investment horizon of 90 days Lyra Therapeutics is expected to under-perform the Immunome. In addition to that, Lyra Therapeutics is 3.22 times more volatile than Immunome. It trades about -0.21 of its total potential returns per unit of risk. Immunome is currently generating about -0.25 per unit of volatility. If you would invest  2,734  in Immunome on March 7, 2024 and sell it today you would lose (1,275) from holding Immunome or give up 46.63% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Lyra Therapeutics  vs.  Immunome

Lyra Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Lyra Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in July 2024. The current disturbance may also be a sign of long term up-swing for the company investors.

Immunome

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Immunome has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in July 2024. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pair Trading with Lyra Therapeutics and Immunome

The main advantage of trading using opposite Lyra Therapeutics and Immunome positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Lyra Therapeutics position performs unexpectedly, Immunome can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immunome will offset losses from the drop in Immunome's long position.

The idea behind Lyra Therapeutics and Immunome pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.